Back to search

University of Thessaly (UTH)

Χαρτογράφηση των Β-λεμφοκυτταρικών επιτόπων του αυτοαντιγόνου Ro52 σε anti-SLA/LP θετικούς και αρνητικούς ασθενείς με αυτοάνοσα νοσήματα του ήπατος

Abstract

dc:description

Autoimmune hepatitis (AIH) is a chronic liver disease of unknownaetiology, which predominates among women. It is characterized byhypergammaglobulinaemia, circulating autoantibodies (Abs), association withHLA DR3 or DR4, interface hepatitis and a favourable response toimmunosuppression.Autoantibodies (Abs) to soluble liver antigen/liver pancreas (anti-SLA/LP)are considered highly specific markers for AIH. They are identified in 10-30%of patients being particularly useful for AIH diagnosis in patients who arenegative for conventional Abs. The molecular target of anti-SLA/LP has beenidentified (SepSecS) with dominant B-cell epitopes and T-cell epitopesdescribed in the carboxyterminal sequence of the autoantigen. Anti-SLA/LPAbs are considered markers of worse prognosis and outcome in patients withAIH, although this assumption has recently been attributed to their frequentco-expression with Abs against Ro52 (anti-Ro52).The aim of the present study was to assess the clinical significance ofanti-SLA/LP Abs alone or in combination with anti-Ro52 in a large cohort ofAIH patients.Furthermore, we aimed to determine the immunodominant Ro52B- cell epitopes in AIH patients with respect to the anti-SLA/LP status.129 consecutive AIH patients were included in the study. Presence of anti-SLA/LP and anti-Ro52 Abs was determined by ELISA and/or immunoblot.Epitope mapping was performed in 26 AIH patients with the use of 78overlapping synthetic 18-mer peptides in ELISA. 12 patients with Sjögrensyndrome and 25 healthy individuals served as controls for epitope mapping. Testing for autoantibodies revealed that 23 of 129 patients with AIH (18%,95% CI: 11-25%) were positive for anti-SLA/LP whereas 49 were positive foranti-Ro52 Abs (38%, 95% CI: 30-47%). Of note, 19 of the 23 patients withreactivity against anti-SLA/LP, co-expressed anti-Ro52 Abs (82.6%, 95% CI:60-94%). Presence of per se anti-SLA/LP or anti-Ro52 Abs or dual reactivitywere not associated with clinical, biochemical or histological characteristics.Response to treatment, weaning of immunosuppression, relapse and overalloutcome were not associated with the presence of the abovementioned Abseither alone or in combination.Ro52 epitope mapping showed that peptides covering aminoacidsequences (aa) 1-18, 277-294, 343-360 και 421-450 were largely identified bypatients with AIH regardless of anti-SLA/LP presence. Moreover, threeconsecutive peptides close to the carboxyterminal end of Ro52 (aa 421-450)were identified exclusively from patients with AIH.In conclusion, neither anti-SLA/LP nor anti-Ro52 Abs or their combinationcould specify a distinct group of AIH patients in terms of clinicalcharacteristics, treatment response and outcome. Ro52 epitope mappingrevealed several immunodominant epitopes in patients with AIH irrespectivelyof their anti-SLA/LP status. Further studies are needed to clarify whether thenewly discovered immunodominant epitopes of Ro52 antigen which wereassociated specifically with AIH are of any clinical or pathogenetic potential inAIH.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gkampeta, Stella
  • Γκαμπέτα, Στέλλα

Subjects

dc:subject × 6

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42340

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gkampeta, Stella; Γκαμπέτα, Στέλλα. Χαρτογράφηση των Β-λεμφοκυτταρικών επιτόπων του αυτοαντιγόνου Ro52 σε anti-SLA/LP θετικούς και αρνητικούς ασθενείς με αυτοάνοσα νοσήματα του ήπατος. University of Thessaly (UTH), 2017. http://hdl.handle.net/10442/hedi/42340